Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Sangamo Therapeutics (SGMO) over the last 17 years, with Q3 2025 value amounting to $29.6 million.

  • Sangamo Therapeutics' Cash & Equivalents fell 2445.09% to $29.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $29.6 million, marking a year-over-year decrease of 2445.09%. This contributed to the annual value of $41.9 million for FY2024, which is 726.93% down from last year.
  • Per Sangamo Therapeutics' latest filing, its Cash & Equivalents stood at $29.6 million for Q3 2025, which was down 2445.09% from $38.3 million recorded in Q2 2025.
  • In the past 5 years, Sangamo Therapeutics' Cash & Equivalents ranged from a high of $178.9 million in Q4 2021 and a low of $25.2 million during Q1 2025
  • Over the past 5 years, Sangamo Therapeutics' median Cash & Equivalents value was $66.8 million (recorded in 2023), while the average stood at $83.4 million.
  • Within the past 5 years, the most significant YoY rise in Sangamo Therapeutics' Cash & Equivalents was 4341.28% (2021), while the steepest drop was 6365.8% (2021).
  • Over the past 5 years, Sangamo Therapeutics' Cash & Equivalents (Quarter) stood at $178.9 million in 2021, then tumbled by 43.85% to $100.4 million in 2022, then tumbled by 55.0% to $45.2 million in 2023, then decreased by 7.27% to $41.9 million in 2024, then fell by 29.35% to $29.6 million in 2025.
  • Its Cash & Equivalents stands at $29.6 million for Q3 2025, versus $38.3 million for Q2 2025 and $25.2 million for Q1 2025.